89bio to initiate Phase III trials for pegozafermin in severe hypertriglyceridaemia

On January 4, 2023, 89bio announced plans to initiate a Phase III clinical trial investigating pegozafermin for patients with severe hypertriglyceridemia in H1 2023, in a business update and outlook for 2023. If Phase III trials and anticipated FDA approval see success, GlobalData predicts 89bio will launch pegozafermin in the US by 2025 for severe hypertriglyceridemia. According to the analyst consensus forecast on the GlobalData Pharma Intelligence Center, the drug is expected to reach $438 million by 2028 and become one of the major players in the dyslipidemia space.